Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

Stock Information for Chimerix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Chimerix Inc.

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Appoints Marc D. Kozin to Board of Directors
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
Chimerix Appoints Lisa Decker to Board of Directors
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.